Metrics of care and cardiovascular outcomes in patients with ST-elevation myocardial infarction treated with pharmacoinvasive strategy: a decade-long network in a populous city in Brazil
Background Pharmacoinvasive strategy is an effective myocardial reperfusion therapy when primary percutaneous coronary intervention (p-PCI) cannot be performed in a timely manner. Methods Authors sought to evaluate metrics of care and cardiovascular outcomes in a decade-long registry of a pharmacoinvasive strategy network for the treatment of ST-elevation myocardial infarction (STEMI). Data from a local network including patients undergoing fibrinolysis in county hospitals and systematically transferred to the tertiary center were accessed from March 2010 to September 2020. Numerical variables were described as median and interquartile range. Area under the curve (AUC-ROC) was used to analyze the predictive value of TIMI and GRACE scores for in-hospital mortality. Results A total of 2,710 consecutive STEMI patients aged 59 [51–66] years, 815 women (30.1%) and 837 individuals with diabetes (30.9%) were analyzed. The time from symptom onset to first-medical-contact was 120 [60–210] minutes and the door-to-needle time was 70 [43–115] minutes. Rescue-PCI was required in 929 patients (34.3%), in whom the fibrinolytic-catheterization time was 7.2 [4.9–11.8] hours, compared to 15.7 [6.8–22,7] hours in those who had successful lytic reperfusion. All cause in-hospital mortality occurred in 151 (5.6%) patients, reinfarction in 47 (1.7%) and ischemic stroke in 33 (1.2%). Major bleeding occurred in 73 (2.7%) patients, including 19 (0.7%) cases of intracranial bleeding. C-statistic confirmed that both scores had high predictive values for in-hospital mortality, demonstrated by TIMI AUC-ROC of 0.80 [0,77–0.84] and GRACE AUC-ROC of 0.86 [0.83—0.89]. Conclusion In a real world registry of a decade-long network for the treatment of ST-elevation myocardial infarction based on the pharmacoinvasive strategy, low rates of in-hospital mortality and cardiovascular outcomes were observed, despite prolonged time metrics for both fibrinolytic therapy and rescue-PCI. Register Clinicaltrials.gov NCT02090712 date of first registration 18/03/2014..
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:23 |
|---|---|
| Enthalten in: |
BMC cardiovascular disorders - 23(2023), 1 vom: 15. Juni |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
De Marqui Moraes, Pedro Ivo [VerfasserIn] |
|---|
| Links: |
Volltext [kostenfrei] |
|---|
| Themen: |
Myocardial Reperfusion |
|---|
| Anmerkungen: |
© The Author(s) 2023 |
|---|
| doi: |
10.1186/s12872-023-03340-6 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
SPR051912988 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | SPR051912988 | ||
| 003 | DE-627 | ||
| 005 | 20230616064722.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 230616s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1186/s12872-023-03340-6 |2 doi | |
| 035 | |a (DE-627)SPR051912988 | ||
| 035 | |a (SPR)s12872-023-03340-6-e | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a De Marqui Moraes, Pedro Ivo |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Metrics of care and cardiovascular outcomes in patients with ST-elevation myocardial infarction treated with pharmacoinvasive strategy: a decade-long network in a populous city in Brazil |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a © The Author(s) 2023 | ||
| 520 | |a Background Pharmacoinvasive strategy is an effective myocardial reperfusion therapy when primary percutaneous coronary intervention (p-PCI) cannot be performed in a timely manner. Methods Authors sought to evaluate metrics of care and cardiovascular outcomes in a decade-long registry of a pharmacoinvasive strategy network for the treatment of ST-elevation myocardial infarction (STEMI). Data from a local network including patients undergoing fibrinolysis in county hospitals and systematically transferred to the tertiary center were accessed from March 2010 to September 2020. Numerical variables were described as median and interquartile range. Area under the curve (AUC-ROC) was used to analyze the predictive value of TIMI and GRACE scores for in-hospital mortality. Results A total of 2,710 consecutive STEMI patients aged 59 [51–66] years, 815 women (30.1%) and 837 individuals with diabetes (30.9%) were analyzed. The time from symptom onset to first-medical-contact was 120 [60–210] minutes and the door-to-needle time was 70 [43–115] minutes. Rescue-PCI was required in 929 patients (34.3%), in whom the fibrinolytic-catheterization time was 7.2 [4.9–11.8] hours, compared to 15.7 [6.8–22,7] hours in those who had successful lytic reperfusion. All cause in-hospital mortality occurred in 151 (5.6%) patients, reinfarction in 47 (1.7%) and ischemic stroke in 33 (1.2%). Major bleeding occurred in 73 (2.7%) patients, including 19 (0.7%) cases of intracranial bleeding. C-statistic confirmed that both scores had high predictive values for in-hospital mortality, demonstrated by TIMI AUC-ROC of 0.80 [0,77–0.84] and GRACE AUC-ROC of 0.86 [0.83—0.89]. Conclusion In a real world registry of a decade-long network for the treatment of ST-elevation myocardial infarction based on the pharmacoinvasive strategy, low rates of in-hospital mortality and cardiovascular outcomes were observed, despite prolonged time metrics for both fibrinolytic therapy and rescue-PCI. Register Clinicaltrials.gov NCT02090712 date of first registration 18/03/2014. | ||
| 650 | 4 | |a ST Elevation Myocardial Infarction |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Thrombolytic Therapy |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Myocardial Reperfusion |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Pharmacoinvasive strategy |7 (dpeaa)DE-He213 | |
| 700 | 1 | |a Galhardo, Attilio |4 aut | |
| 700 | 1 | |a Barbosa, Adriano Henrique Pereira |4 aut | |
| 700 | 1 | |a de Sousa, Jose Marconi Almeida |4 aut | |
| 700 | 1 | |a Alves, Claudia Maria Rodrigues |4 aut | |
| 700 | 1 | |a Bianco, Henrique Tria |4 aut | |
| 700 | 1 | |a dos Santos Povoa, Rui Manuel |4 aut | |
| 700 | 1 | |a Stefanini, Edson |4 aut | |
| 700 | 1 | |a Goncalves, Iran |4 aut | |
| 700 | 1 | |a de Almeida, Dirceu Rodrigues |4 aut | |
| 700 | 1 | |a Fonseca, Francisco Antonio Helfenstein |4 aut | |
| 700 | 1 | |a de Oliveira Izar, Maria Cristina |4 aut | |
| 700 | 1 | |a Moises, Valdir Ambrosio |4 aut | |
| 700 | 1 | |a Lopes, Renato Delascio |4 aut | |
| 700 | 1 | |a Carvalho, Antonio Carlos |4 aut | |
| 700 | 1 | |a Caixeta, Adriano |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t BMC cardiovascular disorders |d London : BioMed Central, 2001 |g 23(2023), 1 vom: 15. Juni |w (DE-627)SPR027329267 |w (DE-600)2059859-2 |x 1471-2261 |7 nnns |
| 773 | 1 | 8 | |g volume:23 |g year:2023 |g number:1 |g day:15 |g month:06 |
| 856 | 4 | 0 | |u https://dx.doi.org/10.1186/s12872-023-03340-6 |z kostenfrei |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_SPRINGER | ||
| 951 | |a AR | ||
| 952 | |d 23 |j 2023 |e 1 |b 15 |c 06 | ||